The meeting discusses the effectiveness and value of treatments for paroxysmal nocturnal hemoglobinuria (PNH). During the session, individual members introduce themselves, disclose conflicts of interest, and emphasize patient experiences. The conversation covers treatment options, particularly the costs, risks, and benefits of new therapies. The meeting aims to balance evidence-based policymaking with the impact of rising healthcare costs, considering both patient needs and broader financial sustainability in healthcare systems.